Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed is indicated for active booster immunization against tetanus, diphtheria, and pertussis. It is approved for use as a single booster dose in individuals aged 10 to 64 years.

Diphtheria, Tetanus, and Pertussis vaccine is prepared from diphtheria toxoid, tetanus toxoid, and pertussis vaccine (inactivated B. pertussis, not less than 4 IU, derived from not more than 20,000 million organisms per 0.5 ml). Supplied as a 0.5 ml ampoule for injection.

Child: Under 5 years: Primary immunization consists of 3 doses of 0.5 ml vaccine administered by intramuscular (IM) or deep subcutaneous (SC) injection, with a minimum interval of 4 weeks between each dose. Over 5 years: Not recommended.

When Diphtheria, Pertussis & Tetanus vaccine is administered together with trivalent inactivated influenza vaccine (TIV) in adults aged 19–64 years, a reduced antibody response to the pertactin antigen has been observed compared to when the vaccine is given alone.

Immunosuppressive therapies may decrease the immune response to the Diphtheria, Pertussis & Tetanus vaccine. Do not mix this vaccine with any other vaccine in the same syringe or vial.

• Severe allergic reaction (e.g., anaphylaxis) to any component of the Diphtheria, Pertussis & Tetanus vaccine or to any diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine
• Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) occurring within 7 days after administration of a previous pertussis-containing vaccine

The most common injection site reactions reported within 0–14 days after vaccination include:

• Adolescents (11–17 years): pain (77.8%), swelling (20.9%), redness (20.8%)
• Adults (18–64 years): pain (65.7%), swelling (21.0%), redness (24.7%)

The most common systemic reactions reported within 0–14 days after vaccination include:

• Adolescents (11–17 years): headache (43.7%), body ache or muscle weakness (30.4%), fatigue (15.1%)
• Adults (18–64 years): headache (33.9%), body ache or muscle weakness (21.9%)

The safety and effectiveness of this vaccine have not been established in pregnant women.

For some presentations of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, the tip caps of prefilled syringes may contain natural rubber latex, which can cause allergic reactions in latex-sensitive individuals.

If Guillain-Barré syndrome occurred within 6 weeks after receiving a previous tetanus toxoid-containing vaccine, the risk of recurrence may increase with subsequent doses.

Vaccination should be postponed in individuals with progressive or unstable neurological disorders. Individuals who experienced an Arthus-type hypersensitivity reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive another dose unless at least 10 years have passed since the last dose.

Syncope (fainting) may occur after injectable vaccines, including Diphtheria, Pertussis & Tetanus vaccines. Appropriate measures should be taken to prevent injury and manage such reactions.

Vaccines, Anti-sera & Immunoglobulin